Ligand Pharmaceuticals Incorporated (LGND) Q1 2018 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.11%

Ligand Pharmaceuticals reported a strong earnings surprise on EPS, which indicates better-than-expected profitability. However, the stock saw a slight decline of 0.11%, suggesting that investors may have been looking for more comprehensive revenue details or guidance. The lack of revenue data and future guidance could contribute to investor caution moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.55	N/A	+32.14%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation and growth. They acknowledged current market conditions but remain focused on long-term goals.

Management highlighted strong performance in their core business.

They noted ongoing investments in R&D to drive future growth.

The team expressed confidence in their strategic direction despite market challenges.

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.11%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.11%

Key numbers

Management commentary